Overview

Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

Status:
Terminated

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with chronic lymphocytic leukemia who are relapsed after receiving prior treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

XOMA (US) LLC